- completedPhase I
A study in healthy male and female volunteers to assess how different formulations of the test medicine (VDPHL01) are taken up by the body
Researchers are testing a new tablet, VDPHL01, designed to treat common pattern hair loss. This early-stage study in healthy volunteers aged 18 to 55 compares how the body absorbs different tablet recipes against an existing medicine (minoxidil). The aim is to check the medicine's safety and blood levels.
United Kingdom · England - recruitingHuman Pharmacology (Phase I)- Other
Randomised, crossover bioavailability clinical trial of oral minoxidil 1 mg, after single and multiple dose administration to healthy volunteers under fasting conditions
This study is looking at how a 1mg dose of minoxidil, a medicine for hair loss, works in healthy women. Researchers want to understand how the body uses this medication after taking it once and over time, under fasting conditions. It's an early-stage study to learn more about the drug.
Spain - recruitingTherapeutic confirmatory (Phase III)
A 6-Month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone (Cortexolone 17α-Propionate) Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-Month Single-Blind Treatment with Clascoterone or Vehicle BID Solution (SCALP 2)
This study is testing a new gel (Clascoterone solution) for men with thinning hair (male-pattern baldness). We want to see if it helps hair grow and if it's safe to use over 6 months, comparing it to a dummy gel.
Germany · Poland - recruitingPHASE3
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This study looks at how well a 1mg minoxidil tablet works for women with hair loss. It compares it to a minoxidil skin solution and a dummy tablet, also checking its safety. It runs for 36 weeks.
Germany - authorisedHuman Pharmacology (Phase I)- Other
Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.
This early-stage study is looking at a new skin cream for hair loss. Researchers want to see if it's safe to use and how well the body absorbs it in healthy people. This is the very first step in testing new treatments.
Poland